Dmitriy M. Ponomarenko

B Lymphocytes Are a Predictive Marker of Eribulin Response and Overall Survival in Locally Advanced or Metastatic Breast Cancer: A Multicenter, Two-Cohort, Non-Randomized, Open-Label, Retrospective Study

V. Perelmuter, E. Choynzonov, E. Kovalenko, 2022, Frontiers in Oncology.

Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

V. A. Rogachev, K. Orishchenko, N. Popova, 2015, BMC Cancer.

A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation

K. Orishchenko, N. Popova, E. Chernykh, 2010, Genetic vaccines and therapy.

Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen

V. A. Rogachev, K. Orishchenko, N. Popova, 2016, BMC Cancer.

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

A. Gasbarrini, W. Li, H. Harputluoglu, 2023, The Lancet.